Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Viking Thera (VKTX)

Viking Thera (VKTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,117,714
  • Shares Outstanding, K 115,894
  • Annual Sales, $ 0 K
  • Annual Income, $ -359,640 K
  • EBIT $ -393 M
  • EBITDA $ -402 M
  • 60-Month Beta 0.83
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 6.28

Options Overview Details

View History
  • Implied Volatility 76.42% (+2.50%)
  • Historical Volatility 53.00%
  • IV Percentile 29%
  • IV Rank 16.41%
  • IV High 170.22% on 08/12/25
  • IV Low 58.01% on 09/04/25
  • Expected Move (DTE 3) 2.33 (6.56%)
  • Put/Call Vol Ratio 0.47
  • Today's Volume 7,858
  • Volume Avg (30-Day) 9,175
  • Put/Call OI Ratio 0.20
  • Today's Open Interest 157,329
  • Open Int (30-Day) 160,936
  • Expected Range 33.20 to 37.86

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.95
  • Number of Estimates 8
  • High Estimate $-0.58
  • Low Estimate $-1.43
  • Prior Year $-0.41
  • Growth Rate Est. (year over year) -131.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
29.88 +18.93%
on 03/30/26
36.79 -3.42%
on 04/15/26
+3.20 (+9.90%)
since 03/20/26
3-Month
25.77 +37.87%
on 02/05/26
37.50 -5.25%
on 03/13/26
+2.01 (+6.00%)
since 01/20/26
52-Week
22.96 +54.75%
on 09/17/25
43.15 -17.66%
on 11/12/25
+11.59 (+48.41%)
since 04/17/25

Most Recent Stories

More News
Viking Therapeutics to Participate at Upcoming Investor Conferences

SAN DIEGO , April 10, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic...

VKTX : 35.53 (+0.94%)
Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735

78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity and Type 2 Diabetes

VKTX : 35.53 (+0.94%)
3 Companies at the Forefront of the GLP-1 Pill Wars

The GLP-1 industry is accelerating growth as adoption rates continue to rise, and these three pharmaceuticals companies could be positioned to capitalize.

VKTX : 35.53 (+0.94%)
LLY : 919.90 (-0.77%)
GPCR : 48.22 (-4.99%)
Viking Therapeutics to Participate at Upcoming Investor Conferences

SAN DIEGO , March 5, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic...

VKTX : 35.53 (+0.94%)
Stocks Plunge on Tech Weakness and AI Fears

The S&P 500 Index ($SPX ) (SPY ) on Thursday closed down -1.57%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down -1.34%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -2.04%. March...

MSTR : 170.81 (+2.58%)
GOOGL : 337.42 (-1.25%)
AAPL : 273.05 (+1.04%)
ICLR : 117.12 (-2.14%)
CSCO : 87.71 (+1.69%)
SNDK : 913.02 (-0.87%)
ADI : 381.05 (+2.58%)
EXPD : 149.31 (+1.36%)
GLXY : 26.80 (+3.72%)
$IUXX : 26,590.34 (-0.31%)
COIN : 211.63 (+2.57%)
ZNM26 : 111-170 (-0.11%)
Stock Indexes Under Pressure as Megacap Tech Stocks Fall

The S&P 500 Index ($SPX ) (SPY ) today is down -0.52%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.07%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -1.08%. March E-mini S&P futures...

GOOGL : 337.42 (-1.25%)
AAPL : 273.05 (+1.04%)
ICLR : 117.12 (-2.14%)
CSCO : 87.71 (+1.69%)
SNDK : 913.02 (-0.87%)
ADI : 381.05 (+2.58%)
EXPD : 149.31 (+1.36%)
$IUXX : 26,590.34 (-0.31%)
ZNM26 : 111-170 (-0.11%)
MSFT : 418.07 (-1.12%)
VKTX : 35.53 (+0.94%)
TSLA : 392.50 (-2.03%)
Stocks Mixed on Strength in Chipmakers and Weakness in Cisco Systems

The S&P 500 Index ($SPX ) (SPY ) today is up +0.20%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.32%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.10%. March E-mini S&P futures (ESH26...

ICLR : 117.12 (-2.14%)
CSCO : 87.71 (+1.69%)
SNDK : 913.02 (-0.87%)
ADI : 381.05 (+2.58%)
$IUXX : 26,590.34 (-0.31%)
ZNM26 : 111-170 (-0.11%)
VKTX : 35.53 (+0.94%)
ESM26 : 7,177.00 (+0.41%)
CHKP : 138.15 (+1.26%)
STX : 539.75 (-1.46%)
WDC : 374.11 (+0.43%)
AMD : 274.95 (-1.24%)
Viking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update

Conference call scheduled for 4:30 p.m. ET today

VKTX : 35.53 (+0.94%)
Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2025 on February 11, 2026

Conference Call Scheduled for Wednesday, February 11 at 4:30 p.m. Eastern Time 

VKTX : 35.53 (+0.94%)
2 ‘Strong Buy’ Growth Stocks With Upside of Around 200%

These growth stocks have the potential to dramatically outperform if you are willing to bear the risks.

VKTX : 35.53 (+0.94%)
CLDX : 34.38 (-0.49%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Viking Therapeutics, Inc. is a biopharmaceutical company. The company is engaged in development of novel therapies for metabolic and endocrine disorders. Its product candidate consists of VK5211, VK0214, VK0612 and VK2809 which are in different clinical trial. Viking Therapeutics, Inc. is based in LA...

See More

Key Turning Points

3rd Resistance Point 36.94
2nd Resistance Point 36.30
1st Resistance Point 35.92
Last Price 35.53
1st Support Level 34.90
2nd Support Level 34.26
3rd Support Level 33.88

See More

52-Week High 43.15
Last Price 35.53
Fibonacci 61.8% 35.44
Fibonacci 50% 33.05
Fibonacci 38.2% 30.67
52-Week Low 22.96

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.